Online citations, reference lists, and bibliographies.
← Back to Search

Oligonucleotide-protamine-albumin Nanoparticles: Protamine Sulfate Causes Drastic Size Reduction.

G. Mayer, V. Vogel, J. Weyermann, D. Lochmann, J. A. van den Broek, C. Tziatzios, W. Haase, Daan Wouters, U. Schubert, A. Zimmer, J. Kreuter, D. Schubert
Published 2005 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Nanoparticles prepared by self-assembly from oligonucleotides (ONs), protamine free base, and human serum albumin ("ternary proticles") are spheres of diameters around 200 nm. Substitution of the protamine free base by protamine sulfate leads to proticles of only around 40 nm in diameter with otherwise unchanged properties. The availability of drug delivery systems of very similar composition but grossly different size may be advantageous when dealing with cells which show size-dependent particle uptake. These nanoparticles are promising candidates for ON delivery to cells because of the following reasons: (1) They are stable for several hours in solutions of up to physiological ionic strength; (2) they are efficiently taken up by cells; (3) after cellular uptake, they easily release the ONs even when these are present as phosphorothioates.
This paper references
10.1016/S0006-3495(02)75469-6
Size-distribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems.
P. Schuck (2002)
10.1016/J.EJPB.2004.04.001
Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: physicochemical characterization.
D. Lochmann (2005)
10.1016/J.JCONREL.2004.02.020
Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation.
N. Dinauer (2004)
10.1016/J.JCONREL.2004.11.029
Oligonucleotide-protamine-albumin nanoparticles: preparation, physical properties, and intracellular distribution.
V. Vogel (2005)
10.1002/1097-0282(20001015)54:5<328::AID-BIP40>3.0.CO;2-P
Determination of the sedimentation coefficient distribution by least-squares boundary modeling.
P. Schuck (2000)
10.1016/S0939-6411(00)00088-6
Cellular delivery of antisense oligonucleotides.
I. Lebedeva (2000)
10.1093/NAR/28.10.E45
Antisense delivery using protamine-oligonucleotide particles.
M. Junghans (2000)
10.1038/sj.gt.3300484
Protamine sulfate enhances lipid-mediated gene transfer
F. Sorgi (1997)
10.1016/J.JCONREL.2004.03.016
Effective intracellular delivery of oligonucleotides in order to make sense of antisense.
F. Shi (2004)
Dynamic Light Scattering: With Applications to Chemistry, Biology, and Physics
B. J. Berne (1976)
10.1080/02652040400000504
Physicochemical characterization of protamine-phosphorothioate nanoparticles
D. Lochmann (2004)
10.1007/978-3-642-71114-5
Thermodynamic data for biochemistry and biotechnology
Hans-Jürgen Hinz (1986)
10.1016/S0939-6411(03)00193-0
Comparison of scanning electron microscopy, dynamic light scattering and analytical ultracentrifugation for the sizing of poly(butyl cyanoacrylate) nanoparticles.
A. Bootz (2004)
10.3109/08982109709035496
Protamine Sulfate Provides Enhanced and Reproducible Intravenous Gene Transfer by Cationic Liposome/DNA Complex
S. Li (1997)
10.1016/S0167-4838(00)00219-3
Phosphodiester and phosphorothioate oligonucleotide condensation and preparation of antisense nanoparticles.
M. Junghans (2001)
10.1023/A:1007548826495
Cationic Polymer Based Gene Delivery Systems
S. D. De Smedt (2004)
10.1007/978-3-642-71114-5_3
Specific Volumes of Biological Macromolecules and Some Other Molecules of Biological Interest
H. Durchschlag (1986)
10.1016/S0006-3495(00)76713-0
Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling.
P. Schuck (2000)
10.1016/J.EJPB.2004.07.014
Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect.
J. Weyermann (2005)
10.1002/POLA.10902
Metallo‐supramolecular micelles: Studies by analytical ultracentrifugation and electron microscopy
V. Vogel (2003)



This paper is referenced by
10.3390/pharmaceutics12050421
Encapsulating TGF-β1 Inhibitory Peptides P17 and P144 as a Promising Strategy to Facilitate Their Dissolution and to Improve Their Functionalization
N. A. Hanafy (2020)
10.1089/oli.2009.0222
Topical application of antisense oligonucleotide-loaded chitosan nanoparticles to rats.
S. Ozbaş-Turan (2010)
10.1016/J.EJPB.2004.07.014
Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect.
J. Weyermann (2005)
10.1016/J.IJPHARM.2006.08.013
Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles.
W. Tiyaboonchai (2007)
10.1080/10717540500494073
Literature Alerts
(2006)
10.1016/j.colsurfb.2009.04.026
Synthesis and characterization of stearyl protamine and investigation of their complexes with DNA for gene delivery.
J. Liu (2009)
10.1016/S1773-2247(10)50056-X
Protein-based nanoparticles as a drug delivery system: chances, risks, perspectives
S. Fuchs (2010)
10.2217/nnm.12.21
Modification of plasmid DNA topology by 'histone-mimetic' gold nanoparticles.
J. Conde (2012)
10.1016/j.ejpb.2014.12.028
Nanoparticle-based technologies for retinal gene therapy.
J. Adijanto (2015)
10.1002/9783527634057.CH35
Albumin‐Drug Nanoparticles
N. Desai (2011)
10.1016/j.ejpb.2010.07.012
Nuclear localization of cationic solid lipid nanoparticles containing Protamine as transfection promoter.
E. Vighi (2010)
10.1016/j.ejpb.2015.04.020
Biodistribution of size-selected lyophilisomes in mice.
E. van Bracht (2015)
10.1158/1535-7163.MCT-09-0402
EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins
J. Winkler (2009)
10.3109/10717544.2011.621989
The role of protamine amount in the transfection performance of cationic SLN designed as a gene nanocarrier
E. Vighi (2012)
10.1039/C0SM00862A
Nanoprecipitation and nanoformulation of polymers: from history to powerful possibilities beyond poly(lactic acid)
S. Schubert (2011)
10.3109/21691401.2014.913054
Effect of size on biological properties of nanoparticles employed in gene delivery
S. Prabha (2016)
10.1201/9781420008449.CH13
Pharmaceutical Applications of Nanoparticulate Drug-Delivery Systems
Y. Pathak (2007)
Nanoparticulate Drug Delivery Systems
Jaya Raja Kumar Kalaimani (2016)
10.1248/BPB.B13-00438
The development of ternary nanoplexes for efficient small interfering RNA delivery.
E. Salva (2013)
10.1007/s11051-013-1651-0
The novel albumin–chitosan core–shell nanoparticles for gene delivery: preparation, optimization and cell uptake investigation
Mahdi Karimi (2013)
10.1371/journal.pone.0164149
Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration
B. Scheicher (2016)
10.4155/TDE.11.56
Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides.
J. Winkler (2011)
10.1016/j.ejps.2015.04.009
Protamine-oligonucleotide-nanoparticles: Recent advances in drug delivery and drug targeting.
B. Scheicher (2015)
10.1016/j.biomaterials.2009.07.067
Characterization and performance of nucleic acid nanoparticles combined with protamine and gold.
R. K. Delong (2009)
10.1155/2014/180549
Protein Nanoparticles as Drug Delivery Carriers for Cancer Therapy
Warangkana Lohcharoenkal (2014)
10.1166/JBN.2014.1878
Self-assembled hyaluronate/protamine polyelectrolyte nanoplexes: synthesis, stability, biocompatibility and potential use as peptide carriers.
A. Umerska (2014)
10.1007/978-981-15-0283-5_7
Bioprotein Based IPN Nanoparticles as Potential Vehicles for Anticancer Drug Delivery: Fabrication Technology
Md Mehedi Hasan (2020)
10.1533/9781908818645.237
12 – Protamine nanoparticles
Surendra Nimesh (2013)
10.1002/9781119041375.CH8
Endogenous Polymers as Biomaterials for Nanoparticulate Gene Therapy
G. K. Zorzi (2015)
Semantic Scholar Logo Some data provided by SemanticScholar